OakChart

BioRestorative Therapies Inc

BRTXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.56+0.03 (1.96%)
2026-11-12 05:10 CET
Market cap
2.15 USD m
Revenue, TTM
0.36 USD m
Net income, TTM
-11.06 USD m
Free cash flow, TTM
-11.90 USD m
EPS diluted, TTM
-22.40
P/E
-
Compare

Price

BRTX against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.0020.0012.9M25.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BRTXclose 1.5620-day 1.5250-day 2.08200-day 5.441.56

94.6% under the 52-week high of 29.00 on 11 Nov 2025. 52-week low 1.28 on 15 Oct 2026. Last 15 sessions, 21.3% high to low

Volume 0.44× normal · the line is the 50-bar volume average

Profile

BRTX
52-week range, 1% of the way up
1.2829.00

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

Employees14
IPOJun 28, 1999
Beta0.83
ATR, 14d0.16
Rel volume0.44
Short float2.80%
Insider own6.22%
Inst own13.17%

Snapshot

6 groups

Valuation

Index-
Market Cap2.15M
Enterprise Value-1.41M
Income-11.06M
Sales0.36M
Book/sh2.38
Cash/sh2.60
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPOJun 28, 1999

Ratios

P/E-
Forward P/E-
PEG-
P/S5.98
P/B0.66
P/C0.60
P/FCF-
EV/EBITDA-
EV/Sales-3.91
Quick Ratio2.35
Current Ratio2.35
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-22.40
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y24.33% 43.92%
Sales past 3/5Y44.27% 36.11%
EPS Y/Y TTM25.62%
Sales Y/Y TTM-8.47%
EPS Q/Q80.98%
Sales Q/Q-7.32%
EarningsMay 20
EPS/Sales Surpr.10.81% -86.67%

Ownership

Insider Own6.22%
Insider Trans0.00%
Inst Own13.17%
Inst Trans9.24%
ROA-147.75%
ROE-241.14%
ROIC-365.43%
Gross Margin33.24%
Oper. Margin-3975.00%
Profit Margin-3089.55%
SMA202.94%
SMA50-25.05%
SMA200-71.34%
Trades-

Technical

Shs Outstand1.38M
Shs Float1.30M
Short Float2.80%
Short Ratio1.24
Short Interest0.04M
52W High29.00 -94.62%
52W Low1.28 21.87%
Volatility5.54% 9.43%
ATR (14)0.16
RSI (14)41.21
Beta0.83
Rel Volume0.44
Avg Volume29.47K
Volume12,847

Performance

Perf Week3.31%
Perf Month-1.89%
Perf Quarter-64.58%
Perf Half Y-58.06%
Perf YTD-93.36%
Perf Year-94.47%
Perf 3Y-95.87%
Perf 5Y-98.98%
Perf 10Y-100.00%
Recom1.00
Target Price20.00
Prev Close1.53
Price1.56
Change %1.96%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 06, 2026DowngradeMMaxim GroupBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
BBLGBone Biologics Corp1.19M
FBLGFibroBiologics Inc6.63M
CELZCreative Medical Technology Holdings Inc4.79M
LGVNLongeveron Inc10.52M
BCDABioCardia Inc13.95M
PLURPluri Inc15.13M
CAPRCapricor Therapeutics Inc652.32M
MESOMesoblast Ltd ADR1.78B
BSEMBioStem Technologies Inc27.45M
LCTXLineage Cell Therapeutics Inc280.72M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • BioRestorative Therapies Announces Reverse Stock Split (GlobeNewswire) -28.76%
  • BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform (GlobeNewswire)
  • BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth (GlobeNewswire)
  • Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) (PR Newswire) +73.30%
  • BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data (GlobeNewswire) +20.10%
  • BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals (GlobeNewswire) -5.82%
  • BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease (GlobeNewswire) -8.09%
  • BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform (GlobeNewswire) +11.60%
  • BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform (GlobeNewswire) -7.82%
  • BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform (GlobeNewswire)
  • BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease (GlobeNewswire) -10.94%
  • BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease (GlobeNewswire) +11.93%
  • BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 (GlobeNewswire)
  • BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-05-20-2.000-4.000-2.4310.580.312
2025Q42026-03-26-6.600-7.400-6.6000.020.152
2025Q32025-11-12-6.600-7.200-6.6660.010.462
2025Q22025-08-12-6.000-7.400-6.0780.300.342
2025Q12025-05-14-12.800-6.500-12.7790.030.382
2024Q42025-03-27-4.000-6.866-4.7290.040.483
2024Q32024-11-13-2.600-8.666-2.6880.260.333
2024Q22024-08-13-10.000-11.400-9.9210.090.013
2024Q12024-05-14-6.600-10.200-6.6650.020.031
2023Q42024-02-28-12.000-13.8004.9820.020.032
2023Q32023-11-29-12.800-13.600-12.8010.030.031
2023Q22023-08-30-15.400-15.900-15.3390.070.072
2023Q12023-05-12-30.600-25.200-30.5810.020.031
2022Q42023-03-24-24.100-28.600-23.7110.000.021
2022Q32023-01-05-25.600--25.5660.00-1
2022Q12022-11-1427.400-12.600-27.3400.020.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-102.2-104.6-73.0950.120.10
2023FY-68.400-70.400-49.3920.150.14
2024FY-23.200-28.134-23.1310.400.86
2025FY-31.600-32.600-31.6000.360.49
2026FY--6.600--2.50
2027FY--5.800--3.13
2028FY--6.600--3.75
2029FY--7.600--4.13
2030FY--7.800--4.54

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2026-07-091000.600.600.60
2026Q2S2026-06-142000.340.070.60
2026Q2S2026-05-202010.340.070.60
2026Q2S2026-03-312010.340.070.60
2026Q2S2026-03-262000.450.300.60
2026Q2S2026-02-112000.450.300.60
2026Q2S2025-11-131000.600.600.60
2026Q2S2025-08-131000.600.600.60
2026Q2S2025-07-161000.600.600.60
2026Q2S2025-07-151000.600.600.60
2026Q2S2025-07-141000.600.600.60
2026Q2S2025-07-131000.600.600.60
2026Q2S2025-07-121000.600.600.60
2026Q2S2025-07-111000.600.600.60

Estimate history

EPS, annual-139200-131246.4-52601.6-571.2-746.009-73.095-49.392-23.131-31.673-22.4018
Period201720182019202020212022202320242025TTM
EPS, quarterly-6.665-9.921-2.688-4.729-12.779-6.078-6.666-7.227-2.431
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual0.0810.1110.130.0770.0460.120.1460.4010.360.36
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0350.0890.2340.0430.0250.3030.0120.020.023
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual000.0010.0360.1760.1840.2350.3460.4441.274
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.3380.3460.3460.3460.3750.3990.3990.4441.274
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.360.360.400.150.120.050.080.130.11
Cost of Goods Sold Incl. D&A0.240.230.220.170.120.21---
Gross Profit0.120.130.18-0.02-0.00-0.16---
Selling, General and Administrative Excl. Other14.3415.7711.7415.2018.9726.152.688.347.52
Research and Development9.3710.095.354.033.510.730.881.721.51
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-14.23-15.65-11.56-15.22-18.97-26.31-2.75-8.43-7.65
Interest Expense--0.000.000.001.821.645.143.22
Unusual Expense-2.98-1.12-1.81-4.00-5.5216.186.881.111.65
Net Income Before Taxes-11.06-14.24-8.98-10.42-13.22-44.30-11.27-14.65-12.52
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-11.06-14.24-8.98-10.42-13.22-44.30-11.27-14.65-12.52
Net Income From Continuing Operations-11.06-14.24-8.98-10.42-13.22-44.30-11.27-14.65-12.52
Net Income-11.06-14.24-8.98-10.42-13.22-44.30-11.27-14.65-12.52
EPS (Recurring)-14.82-33.42-26.39-62.66-94.46-555.29-327.15-49,821.32-119,148.36
EPS (Basic, Before Extraordinaries)-22.40-31.67-23.13-49.39-73.09-746.01-571.20-52,601.60-131,246.40
EPS (Diluted)-22.40-31.67-23.13-49.39-73.09-746.01-571.20-52,601.60-131,246.40
EBITDA-14.01-15.44-11.37-15.06-18.85-26.10-2.60-8.21-7.41
Non-Operating Income (Expense)0.190.280.770.810.230.000.000.030.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.613.332.817.7812.6123.110.691.632.21
Price To Sales Ratio13.4829.3827.6950.3483.05112.06141.480.8661.87
Gross Margin33.2434.9945.85-13.67-0.62-346.10---
Operating Margin-3,975.00-4,350.05-2,881.59-10,439.49-15,838.08-57,191.03-3,574.12-6,486.16-6,889.78
Net Margin-3,089.55-3,959.40-2,239.25-7,145.20-11,036.97-96,311.51-14,639.85-11,267.61-11,277.30
Shares Outstanding1.270.440.350.240.180.180.040.000.00
Market Capitalization2.152.159.908.1210.0315.2819.750.3910.56

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.020.020.010.300.030.040.230.09
Cost of Goods Sold Incl. D&A0.060.050.060.060.050.050.070.05
Gross Profit-0.04-0.03-0.050.24-0.03-0.010.170.03
Selling, General and Administrative Excl. Other3.353.793.663.554.782.682.452.50
Research and Development1.932.632.592.231.711.661.321.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.39-3.83-3.71-3.31-4.81-2.69-2.29-2.47
Interest Expense--0.000.000.000.000.000.00
Unusual Expense-1.22-0.57-0.61-0.570.63-0.93-1.041.74
Net Income Before Taxes-2.15-3.21-3.04-2.66-5.34-1.64-1.09-4.03
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.15-3.21-3.04-2.66-5.34-1.64-1.09-4.03
Net Income From Continuing Operations-2.15-3.21-3.04-2.66-5.34-1.64-1.09-4.03
Net Income-2.15-3.21-3.04-2.66-5.34-1.64-1.09-4.03
EPS (Recurring)-3.39-8.12-7.61-7.00-11.72-6.62-4.47-6.93
EPS (Basic, Before Extraordinaries)-2.43-7.23-6.67-6.08-12.78-4.73-2.69-9.92
EPS (Diluted)-2.43-7.23-6.67-6.08-12.78-4.73-2.69-9.92
EBITDA-3.33-3.77-3.66-3.25-4.76-2.64-2.24-2.42
Non-Operating Income (Expense)0.010.050.060.070.100.120.160.18
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.290.450.400.472.010.180.280.32
Price To Sales Ratio13.4829.0034.4824.0538.0524.6837.4894.70
Gross Margin-158.00-177.92-435.5179.73-118.76-24.0471.5339.18
Operating Margin-14,612.57-19,516.84-31,432.30-1,089.77-19,230.14-6,212.80-979.02-2,770.83
Net Margin-9,298.25-16,365.49-25,748.11-875.79-21,359.20-3,778.63-467.22-4,521.39
Shares Outstanding1.270.440.400.400.380.350.350.35
Market Capitalization2.1510.4311.5713.2913.369.9012.0413.74

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2.9510.7311.0714.7521.033.060.000.120.45
Short Term Receivables0.020.190.020.020.010.020.030.030.04
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.160.220.310.360.440.110.040.030.03
Total Current Assets3.1311.1411.3915.1321.473.190.070.180.52
Net Property, Plant & Equipment0.360.360.510.500.400.500.660.180.33
Total Investments and Advances0.000.000.000.000.000.000.000.000.02
Intangible Assets0.530.620.710.800.590.660.740.810.89
Other Assets0.060.150.000.000.000.000.000.020.00
Total Assets4.0812.2812.6116.4322.454.351.471.191.76
Short Term Debt Incl. Current Port. of LT Debt0.140.000.160.140.180.167.233.633.47
Accounts Payable1.340.480.190.170.050.121.951.892.45
Other Current Liabilities2.243.272.265.670.130.774.533.742.43
Total Current Liabilities3.723.752.615.980.361.0413.729.258.35
Long Term Debt0.000.000.000.160.494.630.520.520.19
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.050.05
Total Liabilities3.723.752.616.140.865.6814.249.838.60
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.010.010.010.020.020.000.000.000.00
Common Equity0.348.529.9910.2821.58-1.33-12.78-8.64-6.84
Total Shareholders Equity0.368.5310.0010.2921.60-1.33-12.78-8.64-6.84
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity0.368.5310.0010.2921.60-1.33-12.78-8.64-6.84
Total Liabilities & Stockholders Equity4.0812.2812.6116.4322.454.351.471.191.76
Book Value Per Share0.7724.6242.4555.88122.61-37.22-13,128.71-58,940.98-89,476.95
Tangible Book Value Per Share-0.4322.8139.4251.51119.26-55.78-13,888.27-64,493.72-101,111.52
Full-Time Employees1411111075699
Price to Book Ratio0.661.160.630.590.71-14.83-0.03-1.22-3.10
Return on Assets-174.11-72.15-71.73-68.00-330.62-387.82-1,101.88-848.38-565.78
Return on Equity-320.47-96.89-80.64-82.93-437.23----
Return on Invested Capital-3,992.21-105.25-104.13-126.50-200.56-341.36---
Quick Ratio0.842.974.372.5359.013.050.010.020.06
Current Ratio0.842.974.372.5359.013.050.010.020.06

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.06-14.24-8.98-10.42-13.22-44.30-11.27-14.65-12.52
Depreciation0.210.210.190.170.120.210.150.220.24
Other Funds (Non Cash)-1.541.930.533.317.1740.448.586.977.22
Funds from Operations-12.39-12.10-8.26-6.95-5.93-3.65-2.54-7.46-5.06
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.571.310.030.520.010.320.570.54-0.05
Cash from Operating Activities-11.82-10.79-8.23-6.43-5.91-3.33-1.96-6.92-5.10
Capital Expenditures-0.08-0.12-0.11-0.17-0.44-0.030.00-0.04-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments7.589.010.623.42-12.960.000.000.000.00
Purchase of Investments-1.70-2.68-20.89-17.54-22.450.000.000.000.00
Sale Or Maturity of Investments9.2811.6921.5120.969.490.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities7.508.900.513.25-13.40-0.030.00-0.04-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.312.967.532.350.000.000.011.660.59
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.312.967.532.350.000.000.011.660.59
Proceedsfrom Stock Options6.312.920.002.350.000.000.001.660.17
Issuance or Reduction of Debt, Net0.000.000.000.000.000.255.025.184.19
Change in Long Term Debt0.000.000.000.000.000.255.025.184.19
Issuance of Long Term Debt0.000.000.000.000.000.255.0210.895.06
Reduction of Long Term Debt0.000.000.000.000.000.000.00-5.71-0.86
Net Financing Active Other Cash Flow-0.10-0.10-0.150.000.0021.070.000.000.00
Other Financing Activities Uses-0.10-0.10-0.150.000.000.000.000.00-0.04
Cash from Financing Activities6.202.857.382.350.0021.325.036.844.78
Net Change in Cash1.880.96-0.34-0.83-19.3117.963.06-0.12-0.33
Free Cash Flow-11.90-10.91-8.34-6.60-6.18-3.36-1.96-6.95-5.12
Preferred Dividends (Cash Flow)------0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments3.592.954.497.389.1110.73
Short Term Receivables0.010.020.010.010.030.19
Inventories0.000.000.000.000.000.00
Other Current Assets0.190.160.200.180.200.22
Total Current Assets3.803.134.707.589.3411.14
Net Property, Plant & Equipment0.330.360.310.340.370.36
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.510.530.560.580.600.62
Other Assets0.000.060.080.020.020.15
Total Assets4.644.085.648.5210.3312.28
Short Term Debt Incl. Current Port. of LT Debt0.030.140.000.000.000.00
Accounts Payable0.671.340.860.610.600.48
Other Current Liabilities0.912.242.583.063.583.27
Total Current Liabilities1.613.723.443.674.183.75
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.613.723.443.674.183.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.010.010.010.010.01
Common Equity3.030.342.194.836.138.52
Total Shareholders Equity3.030.362.214.856.148.53
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3.030.362.214.856.148.53
Total Liabilities & Stockholders Equity4.644.085.648.5210.3312.28
Book Value Per Share2.380.775.5012.1116.3424.62
Tangible Book Value Per Share1.97-0.434.1010.6614.7422.81
Full-Time Employees-14---11
Price to Book Ratio0.6630.435.282.752.181.16
Return on Assets-147.75-174.11-125.35-87.06-85.55-72.15
Return on Equity-241.14-320.47-207.73-137.09-117.16-96.89
Return on Invested Capital-71.20-899.14-137.67-54.82-86.90-19.18
Quick Ratio2.350.841.372.062.232.97
Current Ratio2.350.841.372.062.232.97

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-2.15-3.21-3.04-2.66-5.34-1.64
Depreciation0.050.050.050.050.050.05
Other Funds (Non Cash)-0.94-0.16-0.27-0.182.54-0.85
Funds from Operations-3.04-3.31-3.26-2.78-2.75-2.44
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.770.900.360.09-0.030.09
Cash from Operating Activities-3.81-2.42-2.90-2.69-2.78-2.35
Capital Expenditures0.00-0.080.000.00-0.04-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.972.482.002.132.401.55
Purchase of Investments-0.070.00-0.55-1.08-1.05-2.59
Sale Or Maturity of Investments1.042.482.553.213.464.14
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.972.402.002.132.371.53
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00-0.00---
Change in Capital Stock4.440.980.000.891.090.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.440.980.000.891.090.00
Proceedsfrom Stock Options4.440.980.000.891.050.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.06-0.050.000.00-0.13
Other Financing Activities Uses0.00-0.06-0.050.000.00-0.13
Cash from Financing Activities4.440.92-0.050.891.09-0.13
Net Change in Cash1.600.91-0.950.330.68-0.94
Free Cash Flow-3.81-2.49-2.90-2.69-2.82-2.36

Revenue breakdown

Product2024: 300.00K 2025: 300.00K
Royalty2024: 101.00K 2025: 59.70K
United States2024: 401.00K 2025: 359.70K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.80%0.0M1.3M30.18K
2026-10-151.14%0.0M1.3M26.80K
2026-09-301.02%0.0M1.3M22.43K
2026-09-150.90%0.0M1.3M21.64K
2026-08-31-0.0M-31.42K
2026-08-140.42%0.0M1.2M501.02K
2026-07-311.95%0.0M1.2M507.50K
2026-07-153.31%0.0M1.2M521.93K
2026-06-304.74%0.1M1.2M524.61K
2026-06-155.50%0.1M1.2M543.01K
2026-05-2928.27%0.3M1.2M689.50K
2026-05-151.58%0.0M1.2M434.43K
2026-04-302.77%0.0M1.2M484.51K
2026-04-152.89%0.0M1.1M482.02K
2026-03-315.36%0.0M0.8M469.54K
2026-03-139.35%0.1M0.7M436.10K
2026-02-275.59%0.0M0.7M272.17K
2026-02-1320.79%0.1M0.3M54.48K
2026-01-301.92%0.0M0.3M2.30K
2026-01-151.92%0.0M0.3M6.58K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-098-KCurrent report2026-10-07SEC
2026-09-118-KCurrent report2026-09-04SEC
2026-09-108-K/A2026-08-26SEC
2026-09-028-KCurrent report2026-09-02SEC
2026-09-028-KCurrent report2026-08-26SEC
2026-08-258-KCurrent report2026-08-21SEC
2026-08-14NT 10-Q2026-06-30SEC
2026-08-148-KCurrent report2026-08-07SEC
2026-08-03SCHEDULE 13G/ASEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-13SEC
2026-07-243Initial statement of beneficial ownership of securities2026-07-14SEC
2026-07-168-KCurrent report2026-07-08SEC
2026-06-183Initial statement of beneficial ownership of securities2026-06-10SEC
2026-06-183Initial statement of beneficial ownership of securities2026-06-10SEC
2026-06-173Initial statement of beneficial ownership of securities2026-06-10SEC
2026-06-128-KCurrent report2026-06-10SEC
2026-06-128-KCurrent report2026-06-10SEC
2026-05-298-KCurrent report2026-05-26SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-018-KCurrent report2026-05-01SEC
2026-04-30424B3SEC
2026-04-28EFFECTEffectiveness filing by commission orderSEC
2026-04-27POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-238-KCurrent report2026-04-23SEC
2026-04-20POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-04-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-26SEC
2026-04-03PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-26SEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-23SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC3.15%
HRT FINANCIAL LP2.79%
XTX Topco Ltd1.12%
CITADEL ADVISORS LLC1.07%
VANGUARD FIDUCIARY TRUST CO0.71%
GEODE CAPITAL MANAGEMENT, LLC0.60%
UBS Group AG0.25%
WEALTH ALLIANCE, LLC0.16%
STATE STREET CORP0.13%
Keystone Financial Group0.11%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.50%
Fidelity Total Market Index Fund0.05%
Fidelity Series Total Market Index Fund0.03%
Fidelity Nasdaq Composite Index Fund0.02%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. BRTX. Cached 15 minutes.

Some panels did not load: insider.